Mario Gabelli Myovant Sciences Ltd. Transaction History

Gamco Investors, Inc. Et Al

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	BUY	$24.03 - $27.02 $2.5 Million - $2.81 Million	103,879 New	103,879 $2.8 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.